PHAR (Pharming Group) NonCurrent Deferred Liabilities: $0.0 Mil (As of Mar. 2026)


PHAR Pharming Group PHAR
77 GF Score
Price $13.42
GF Value $14.74
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group NonCurrent Deferred Liabilities?

Pharming Group PHAR -2.19% 77 NonCurrent Deferred Liabilities is $0.0 Mil as of Mar. 2026. GuruFocus rates PHAR with a GF Score™ of 77/100 and a GF Value™ of $14.74 (Fairly Valued). The stock has 1 warning sign investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Pharming Group's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.0 Mil.

Pharming Group NonCurrent Deferred Liabilities Related Terms

Pharming Group NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Pharming Group's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group NonCurrent Deferred Liabilities Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharming Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PHAR
77GF Score
Pharming Group PHAR
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.0 Mil mean?
Pharming Group (PHAR) has a NonCurrent Deferred Liabilities of $0.0 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Pharming Group and its competitors.
Is Pharming Group's NonCurrent Deferred Liabilities too high?
Pharming Group's current NonCurrent Deferred Liabilities is $0.0 Mil. Overall, Pharming Group has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's NonCurrent Deferred Liabilities compare to VRTX and REGN?
Pharming Group's NonCurrent Deferred Liabilities of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Pharming Group and its competitors. Pharming Group's current NonCurrent Deferred Liabilities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.74, compared to a current price of $13.42 — trading 9% below its estimated fair value. The current NonCurrent Deferred Liabilities is $0.0 Mil. Pharming Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Pharming Group (PHAR), the current NonCurrent Deferred Liabilities is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $13.42 is trading 9% below its estimated GF Value™ of $14.74. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHAR:

  • NonCurrent Deferred Liabilities: $0.0 Mil
  • GF Value™: $14.74 vs. price of $13.42 (9% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
77GF Score

Get the complete analysis for PHAR

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.42
Price
$14.74
GF Value